Floatz logo

ADUCANUMAB

Alzheimer Disease 1

Ali Rezaimonoclonal_antibodyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Alzheimer Disease 1 cohort.

Asset / SponsorPhaseRating
Aph-1105
Aphios
Phase 2CCC
LECANEMAB
Ali Rezai
Early Phase 1C
nio752
University College, London
Phase 1NR

Same molecule, other indications

ADUCANUMAB is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
55 / 100
View asset →
Mild Cognitive Impairment (MCI)Dormant
CCC
Indicative ·
52 / 100
View asset →
cognitive disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →